Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon V Tiu

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Cell Reports|December 3, 2014
Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven LeukemogenesisAnindya Chatterjee, Joydeep Ghosh, Baskar Ramdas, et al.
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Cancer Cell|September 13, 2011
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABLRaghuveer Singh Mali, Baskar Ramdas, Peilin Ma, et al.
Plos One|August 21, 2012
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosisFabiola Traina, Valeria Visconte, Anna M Jankowska, et al.
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood|July 25, 2012
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromesValeria Visconte, Heesun J Rogers, Jarnail Singh, et al.
Blood|May 4, 2012
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesisAndres Jerez, Yuka Sugimoto, Hideki Makishima, et al.
Molecular Cancer Therapeutics|February 4, 2021
ERK Inhibitor LY3214996-Based Treatment Strategies for <i>RAS</i>-Driven Lung CancerJens Köhler, Yutong Zhao, Jiaqi Li, et al.
Haematologica|January 28, 2014
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group studyHeesun J Rogers, James W Vardiman, John Anastasi, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Cell Reports|December 3, 2014
Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven LeukemogenesisAnindya Chatterjee, Joydeep Ghosh, Baskar Ramdas, et al.
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Cancer Cell|September 13, 2011
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABLRaghuveer Singh Mali, Baskar Ramdas, Peilin Ma, et al.
Plos One|August 21, 2012
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosisFabiola Traina, Valeria Visconte, Anna M Jankowska, et al.
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood|July 25, 2012
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromesValeria Visconte, Heesun J Rogers, Jarnail Singh, et al.
Blood|May 4, 2012
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesisAndres Jerez, Yuka Sugimoto, Hideki Makishima, et al.
Molecular Cancer Therapeutics|February 4, 2021
ERK Inhibitor LY3214996-Based Treatment Strategies for <i>RAS</i>-Driven Lung CancerJens Köhler, Yutong Zhao, Jiaqi Li, et al.
Haematologica|January 28, 2014
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group studyHeesun J Rogers, James W Vardiman, John Anastasi, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Pageof 9